Sex Differences in Amyotrophic Lateral Sclerosis Survival and Progression: A Multidimensional Analysis.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
03 Apr 2024
03 Apr 2024
Historique:
revised:
15
03
2024
received:
12
01
2024
accepted:
19
03
2024
medline:
3
4
2024
pubmed:
3
4
2024
entrez:
3
4
2024
Statut:
aheadofprint
Résumé
To investigate sex-related differences in amyotrophic lateral sclerosis (ALS) prognosis and their contributing factors. Our primary cohort was the Piemonte and Aosta Register for ALS (PARALS); the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) and the Answer ALS databases were used for validation. Survival analyses were conducted accounting for age and onset site. The roles of forced vital capacity and weight decline were explored through a causal mediation analysis. Survival and disease progression rates were also evaluated after propensity score matching. The PARALS cohort included 1,890 individuals (44.8% women). Men showed shorter survival when stratified by onset site (spinal onset HR 1.20, 95% CI 1.00-1.44, p = 0.0439; bulbar onset HR 1.36, 95% CI 1.09-1.70, p = 0.006917), although women had a steeper functional decline (+0.10 ALSFRS-R points/month, 95% CI 0.07-0.15, p < 0.00001) regardless of onset site. Instead, men showed worse respiratory decline (-4.2 forced vital capacity%/month, 95% CI -6.3 to -2.2, p < 0.0001) and faster weight loss (-0.15 kg/month, 95% CI -0.25 to -0.05, p = 0.0030). Causal mediation analysis showed that respiratory function and weight loss were pivotal in sex-related survival differences. Analysis of patients from PRO-ACT (n = 1,394, 40.9% women) and Answer ALS (n = 849, 37.2% women) confirmed these trends. The shorter survival in men is linked to worse respiratory function and weight loss rather than a faster disease progression. These findings emphasize the importance of considering sex-specific factors in understanding ALS pathophysiology and designing tailored therapeutic strategies. ANN NEUROL 2024.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero dell'Università e della Ricerca
ID : 2017SNW5MB
Organisme : Ministero della Salute
ID : RF-2016-02362405
Organisme : American Academy of Neurology
Organisme : Joint Programme Neurodegenerative Disease Research (JPND)
Organisme : Seventh Framework Programme
ID : 259867
Organisme : ALS Association
Organisme : American Brain Foundation
Informations de copyright
© 2024 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol 2019;32:771–776. https://doi.org/10.1097/WCO.0000000000000730.
Chiò A, Moglia C, Canosa A, et al. ALS phenotype is influenced by age, sex, and genetics: a population‐based study. Neurology 2020;94:e802–e810. https://doi.org/10.1212/WNL.0000000000008869.
Palmieri A, Mento G, Calvo V, et al. Female gender doubles executive dysfunction risk in ALS: a case‐control study in 165 patients. J Neurol Neurosurg Psychiatry 2015;86:574–579. https://doi.org/10.1136/jnnp-2014-307654.
Knibb JA, Keren N, Kulka A, et al. A clinical tool for predicting survival in ALS. J Neurol Neurosurg Psychiatry 2016;87:1361–1367. https://doi.org/10.1136/jnnp-2015-312908.
Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018;17:423–433. https://doi.org/10.1016/S1474-4422(18)30089-9.
Su WM, Cheng YF, Jiang Z, et al. Predictors of survival in patients with amyotrophic lateral sclerosis: a large meta‐analysis. EBioMedicine 2021;74:103732. https://doi.org/10.1016/j.ebiom.2021.103732.
Ortholand J, Pradat PF, Tezenas du Montcel S, Durrleman S. Interaction of sex and onset site on the disease trajectory of amyotrophic lateral sclerosis. J Neurol 2023;270:5903–5912. https://doi.org/10.1007/s00415-023-11932-7.
Chiò A, Mora G, Moglia C, et al. Piemonte and Valle d'Aosta register for ALS (PARALS) secular trends of amyotrophic lateral sclerosis. JAMA Neurology 2017;74:1097–1104. https://doi.org/10.1001/jamaneurol.2017.1387.
Shefner JM, Al‐Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol 2020;131:1975–1978. https://doi.org/10.1016/j.clinph.2020.04.005.
Atassi N, Berry J, Shui A, et al. The PRO‐ACT database: design, initial analyses, and predictive features. Neurology 2014;83:1719–1725. https://doi.org/10.1212/WNL.0000000000000951.
Baxi EG, Thompson T, Li J, et al. Answer ALS, a large‐scale resource for sporadic and familial ALS combining clinical and multi‐omics data from induced pluripotent cell lines. Nat Neurosci 2022;25:226–237. https://doi.org/10.1038/s41593-021-01006-0.
van Eijk RPA, Bakers JNE, van Es MA, et al. Implications of spirometric reference values for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degene 2019;20:473–480. https://doi.org/10.1080/21678421.2019.1634736.
Quanjer PH, Stanojevic S, Cole TJ, et al. Multi‐ethnic reference values for spirometry for the 3‐95‐yr age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324–1343. https://doi.org/10.1183/09031936.00080312.
Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis ‐ frontotemporal spectrum disorder (ALS‐FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:153–174. https://doi.org/10.1080/21678421.2016.1267768.
Rijnhart JJM, Lamp SJ, Valente MJ, et al. Mediation analysis methods used in observational research: a scoping review and recommendations. BMC Med Res Methodol 2021;21:226. https://doi.org/10.1186/s12874-021-01426-3.
Wang W, Xu J, Schwartz J, et al. Causal mediation analysis with latent subgroups. Stat Med 2021;40:5628–5641. https://doi.org/10.1002/sim.9144.
McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med 2010;7:557–570. https://doi.org/10.1016/j.genm.2010.11.010.
Watanabe H, Atsuta N, Nakamura R, et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:230–236. https://doi.org/10.3109/21678421.2014.990036.
Gautier G, Verschueren A, Monnier A, et al. ALS with respiratory onset: clinical features and effects of non‐invasive ventilation on the prognosis. Amyotroph Lateral Scler 2010;11:379–382. https://doi.org/10.3109/17482960903426543.
Pinto S, Gromicho M, Oliveira Santos MO, et al. Respiratory onset in amyotrophic lateral sclerosis: clinical features and spreading pattern. Amyotroph Lateral Scler Frontotemporal Degener 2023;24:40–44. https://doi.org/10.1080/21678421.2022.2067777.
Chio A, Calvo A, Moglia C, et al. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2011;82:740–746. https://doi.org/10.1136/jnnp.2010.235952.
Moglia C, Calvo A, Grassano M, et al. Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population‐based cohort. J Neurol Neurosurg Psychiatry 2019;90:666–673. https://doi.org/10.1136/jnnp-2018-319611.
Desport JC, Torny F, Lacoste M, et al. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2005;2:202–207. https://doi.org/10.1159/000089626.
Janse van Mantgem MR, van Eijk RPA, van der Burgh HK, et al. Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population‐based study. J Neurol Neurosurg Psychiatry 2020;91:867–875. https://doi.org/10.1136/jnnp-2020-322909.
Steyn FJ, Ngo ST. Prognostic value of weight loss in patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2020;91:813. https://doi.org/10.1136/jnnp-2020-323440.
Bede P, Elamin M, Byrne S, Hardiman O. Sexual dimorphism in ALS: exploring gender‐specific neuroimaging signatures. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:235–243. https://doi.org/10.3109/21678421.2013.865749.
Pede D. Sex‐related differences in amyotrophic lateral sclerosis: a brain 2‐[18F]FDG‐PET study. Eur J Neurol 2023;30:120–329. https://doi.org/10.1111/ene.15949.
Kodama L, Gan L. Do microglial sex differences contribute to sex differences in neurodegenerative diseases? Trends Mol Med 2019;25:741–749. https://doi.org/10.1016/j.molmed.2019.05.001.
Murdock BJ, Goutman SA, Boss J, et al. Amyotrophic lateral sclerosis survival associates with neutrophils in a sex‐specific manner. Neurol Neuroimmunol Neuroinflamm 2021;8:e953. https://doi.org/10.1212/NXI.0000000000000953.
Murdock BJ, Famie JP, Piecuch CE, et al. Natural killer cells associate with amyotrophic lateral sclersois in a sex‐ and age‐dependent manner. JCI Insight 2021;6:e147129. https://doi.org/10.1172/jci.insight.147129.
Grassano M, Manera U, De Marchi F, et al. The role of peripheral immunity in ALS: a population‐based study. Ann Clin Transl Neurol 2023;10:1623–1632. https://doi.org/10.1002/acn3.51853.
Sumien N, Cunningham JT, Davis DL, et al. Neurodegenerative disease: roles for sex, hormones, and oxidative stress. Endocrinology 2021;162:bqab185. https://doi.org/10.1210/endocr/bqab185.
Raymond J, Mehta P, Larson T, et al. Reproductive history and age of onset for women diagnosed with amyotrophic lateral sclerosis: data from the national ALS registry: 2010–2018. Neuroepidemiology 2021;55:416–424. https://doi.org/10.1159/000516344.
Gordon PH, Cheng B, Salachas F, et al. Progression in ALS is not linear but is curvilinear. J Neurol 2010;257:1713–1717. https://doi.org/10.1007/s00415-010-5609-1.